天堂网亚洲,天天操天天搞,91视频高清,菠萝蜜视频在线观看入口,美女视频性感美女视频,95丝袜美女视频国产,超高清美女视频图片

ChemicalBook >> journal list >> Epilepsy and Behavior Case Reports >>article

Epilepsy and Behavior Case Reports

Download PDF

Lacosamide may improve cognition in patients with focal epilepsy: EpiTrack to compare cognitive side effects of lacosamide and carbamazepine

Published:1 January 2018 DOI: 10.1016/j.ebcr.2018.02.004 PMID: 29977793
Claudio Liguori , Francesca Izzi , Natalia Manfredi , Nicola Biagio Mercuri , Fabio Placidi

Abstract

Carbamazepine (CBZ) is a first generation anti-seizure drug, considered as first choice therapy in focal epilepsy but associated with cognitive side effects. Lacosamide (LCM) is a third-generation anti-seizure drug approved for treating focal epilepsy. This case series documented the comparable efficacy of LCM and CBZ as first add on treatments in patients affected by uncontrolled focal seizures. LCM showed an increase in EpiTrack scores, which measure cognitive abilities, at follow-up compared to CBZ. This preliminary data may represent the basis for future prospective studies aimed at comparing the long-term cognitive side effects of LCM and CBZ.

Substances (2)

Related products
Procduct Name CAS Molecular Formula Supplier Price
Carbamazepine 298-46-4 C15H12N2O 742 suppliers $7.00-$2055.90
Lacosamide 175481-36-4 C13H18N2O3 506 suppliers $49.00-$278.00

Similar articles

IF:6.6

Long-term safety and efficacy of lacosamide and controlled-release carbamazepine monotherapy in patients with newly diagnosed epilepsy

Epilepsia Elinor Ben-Menachem, Hans Peter Grebe,etc Published: 21 November 2019
IF:2.2

Management of prostacyclin side effects in adult patients with pulmonary arterial hypertension.

Pulmonary Circulation Martha Kingman, Christine Archer-Chicko,etc Published: 1 July 2017
IF:5.3

Meyler's side effects of drugs 11th edition

International Journal of Pharmaceutics P.F. D'Arcy,etc Published: 20 April 1990